

CURRICULUM VITAE

Name: M. Michael Wolfe, M.D.

Education:
1972 B.S. (cum laude) Ohio State University, Columbus, OH
1976 M.D. Ohio State University College of Medicine, Columbus, OH

Postdoctoral Training:

Internships and Residencies:

1976-1979 Internship and Residency in Internal Medicine, Hospital of the Medical College of Pennsylvania, Philadelphia, PA
1978-1979 Chief Resident, Internal Medicine, Hospital of the Medical College of Pennsylvania, Philadelphia, PA

Clinical and Research Fellowships:

1979-1981 Research Fellow in Medicine (Gastroenterology; U.S. Public Health Service), University of Florida School of Medicine, Gainesville, FL
1981-1982 Clinical Fellow in Medicine (Gastroenterology), University of Florida School of Medicine, Gainesville, FL

Licensure and Certification:

1977-1979 Pennsylvania Medical License
1979-1986 Florida Medical License
1979- Diplomat, American Board of Internal Medicine #69204
1981- Diplomat in Gastroenterology, ABIM #69204
1985- Massachusetts Medical License, #54819

Academic Appointments:

1981-1982 Instructor in Medicine (Gastroenterology), University of Florida School of Medicine, Gainesville, FL
1982-1985 Assistant Professor of Medicine (Gastroenterology), University of Florida School of Medicine, Gainesville, FL
1985-1994 Assistant Professor of Medicine, Harvard Medical School, Boston, MA
1994-1996 Associate Professor of Medicine, Harvard Medical School, Boston, MA
1996-1998 Associate Professor of Medicine, Boston University School of Medicine, Boston, MA
1996-2010 Chief, Section of Gastroenterology, Boston University School of Medicine, Boston, MA

1997-1998	Research Associate Professor of Physiology, Boston University School of Medicine, Boston, MA
1998-2010	Professor of Medicine, Boston University School of Medicine, Boston, MA
1998-2010	Research Professor of Physiology and Biophysics, Boston University School of Medicine, Boston, MA
2010-	Charles H. Rammelcamp, Jr. Professor of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
2010-	Chair of the Case Western Reserve University Department of Medicine at MetroHealth Medical Center, Cleveland, OH
2010-	Professor of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH

Hospital Appointments:

1982-1985	Staff Physician in Medicine (Gastroenterology) Gainesville Veterans Administration Medical Center, Gainesville, FL
1982-1985	Staff Physician in Medicine (Gastroenterology, Hepatology, and Nutrition), Shands Hospital, University of Florida, Gainesville, FL
1985-1989	Senior Associate in Medicine, Beth Israel Hospital, Boston, MA
1989-1996	Associate Physician, Brigham and Women's Hospital, Boston, MA
1996	Physician, Brigham and Women's Hospital, Boston, MA
1996-2010	Staff Physician in Medicine (Gastroenterology), Boston Medical Center, Boston, MA
1996-2010	Chief, Section of Gastroenterology, Boston University Medical Center, Boston Medical Center, and Boston University School of Medicine, Boston, MA
2010-	Chair, Department of Medicine, MetroHealth Medical Center, Cleveland, OH

Other Professional Positions:

1994-1996	Director, Radioimmunoassay Core of the Harvard Digestive Diseases Center, Harvard Medical School, Boston, MA
1989-1994	Associate Director, Immunology Core of the Harvard Digestive Diseases Center, Harvard Medical School, Boston, MA
1994-1996	Director, Clinical Research Unit, Gastroenterology Division, Brigham and Women's Hospital, Boston, MA
1994-1996	Co-Director, Longwood APUDoma Group, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA

Awards and Honors:

1968-1972	Honors Program of the College of Arts and Sciences, Ohio State University, Columbus, OH
1971	Alpha Epsilon Delta Pre-Medical Honorary, Ohio State University, Columbus, OH
1973	Phi Beta Kappa, Ohio State University, Columbus, OH
1982	Biomedical Research Support Grant Allocation, University of Florida School of Medicine, Gainesville, FL
1984-1987	AGA/Pharmacia Research Scholar Award
1995-	Fellow, American College of Gastroenterology
1997-	Fellow, American College of Physicians
2001-2003	Chair, FDA Advisory Committee for GI Drugs
2004	Hadassah Northeast Physician Recognition Award
2004-2010	Castle Connolly list of America's Top Doctors
2006	Ignition Award from Boston University Office of Technology Development
2006-	Fellow, American Gastroenterological Association
2007-	Alpha Omega Alpha, alumni inductee, Gamma Chapter of The Ohio State University
2008-2011	Hartwell Foundation Scholar
2008-2009	Boston Magazine List of Top Doctors

Major Committee Assignments:

Medical School:

1973-1974	Class Vice President, Ohio State University College of Medicine, Columbus, OH
1973-1979	Member, Student Council, Ohio State University College of Medicine, Columbus, OH
1973-1974	Member, Curriculum Committee, Ohio State University College of Medicine, Columbus, OH
1975-1976	Landacre Society Medical School Research, Columbus, OH
1997-	Member, Advisory Committee for Obesity Center at Boston University School of Medicine
1998-2006	Member, Advisory Committee for Boston University School of Medicine General Clinical Research Center
2003-	Member, 7-year Admissions Committee, Boston University

Hospital:

1978-1979	Member, Hospital Audit Committee, Philadelphia Veterans
-----------	---

1978-1979	Administration Hospital, Philadelphia, PA Member, Hospital Pharmacy Committee, Philadelphia Veterans Administration Hospital, Philadelphia, PA
1978-1979	Member, Records Committee, Hospital of the Medical College of Pennsylvania, Philadelphia, PA
1986-1989	Member, Hospital Transfusion Committee, Beth Israel Hospital, Boston, MA
1990-1996	Member, Internship Selection Committee, Department of Medicine, Brigham and Women's Hospital
1996-2000	Member, Executive Committee, Boston University Medical Group
1997-	Member, Medical Executive Committee of the Medical and Dental Staff, Boston University Medical Center
2004-	Member, Management Services Contracts Committee, Boston Medical Center

Department of Medicine:

1997-1998	Co-Chair, Ad hoc Committee to establish the Ingelfinger Center for Excellence in Gastroenterology
1997-1998	Member, Clinical Care Strategic Planning Committee
1998-2000	Member, Research Committee
1997-2003	Chair, Evans Research Week Committee

Memberships, Offices and Committee Assignments in Professional Societies:

1977-1982	Associate, American College of Physicians
1979-1982	Associate, American Gastroenterological Association
1982-	Member, American College of Physicians
1982-	Member, American Gastroenterological Association
1982-1993	American Federation for Clinical Research
1982-1985	Alachua County Medical Society
1982-1985	Florida Medical Association
1983-	American Society for Gastrointestinal Endoscopy
1984-1987	Tissue Culture Association
1984-1990	American Pancreatic Association
1984-	Gastroenterology Research Group
1984-	American Association for the Advancement of Science
1988	Acting Associate Editor, <i>Gastroenterology</i>
1988	Co-Chair, GI Hormone Session, Annual Meeting of the
1989	Chair, GI Hormone Session, Annual Meeting of the American Gastroenterological Association
1989-1996	Editorial Board, <i>Peptide Therapy Index & Reviews</i>
1990-	American Physiological Society
1990-1992	<i>Ad hoc</i> Member, VA Grant Study Section on Gastroenterology
1990-1993	Contributor, Selected Summaries Section, <i>Gastroenterology</i>
1991-1993	Member, Committee on Constitution and Bylaws, American Gastroenterological Association
1993	Co-Chair, Esophageal, Gastric, and Duodenal Secretions

	Session, Annual Meeting of the American Gastroenterological Association
1993-1996	Chair, Committee on Constitution and Bylaws, American Gastroenterological Association
1995-1998	Member, Member Giving Committee, American Digestive Health Foundation
1995-	Editorial Board, <i>Digestive Diseases and Sciences</i>
1995-	Fellow, American College of Gastroenterology
1996-	Fellow, American College of Physicians
1997-2002	Editorial Board, <i>Alimentary Pharmacology & Therapeutics</i>
1997-2000	Member, Research Committee, American Gastroenterological Association
2000-2001	Chair, GERD Awareness Program (GAP), American Gastroenterological Association
2000-2008	Member, ZRG1 F10 Study Section, NIDDK
2000-2003	Member, GI Advisory Committee, U.S. Food and Drug Administration
2001-2003	Chair, GI Advisory Committee, U.S. Food and Drug Administration
2002-2005	Member, Education Committee, American Gastroenterological Association
2002-	Editorial Board, <i>Regulatory Peptides</i>
2003-2009	Editorial Board, <i>American Journal of Physiology</i>
2004-	Member, North American Association for the Study of Obesity (NAASO)
2005-	Member, American Association for Cancer Research (AACR)
2005	Co-Chair, Combined Meeting of the American and Israeli Gastroenterological Associations; Dead Sea, Israel, January 6-7, 2005
2005	Chair, <i>AGA-Abbott Immunology Investing in the Future</i> ; Digestive Disease Week; May 15-18, 2005, Chicago, IL
2005-2006	Co-Chair, American Gastroenterological Association, Gastroenterology Core Curriculum Steering Committee
2006	Co-Chair, Gastroenterology Division Chief Meeting, American Gastroenterological Association
2006-	Fellow, American Gastroenterological Association
2006-	Steering Committee, International GI Regulatory Peptide Society
2010-2012	Counselor, Nutrition and Obesity Section, American Gastroenterological Association

Major Research Interests:

1. Investigation of the physiologic significance of glucose-dependent insulinotropic polypeptide (GIP) and its role in the pathogenesis of obesity and diabetes mellitus.
2. Development of novel forms of therapy for obesity and other metabolic

disorders and treatment of acid-related disorders.

3. The role and mechanisms of GI peptides in gastrointestinal carcinogenesis.

Research Funding Information:

<u>Past:</u>	1984-1987	NIH/K08	PI	GI Peptide Regulation of Gastric Acid Secretion.
	1984-1987	American Gastroenterological Association	PI	GI Peptide Regulation of Gastric Acid Secretion in the Isolated Rat Stomach.
	1986-1988	NIH/P30	PI (pilot study)	Biosynthesis of Rat Antral gastrin.
	1986-1989	NIH/P30	Core Director (Radioimmunoassay)	Structure-Function Relationships in the Alimentary Tract.
	1987-1990	NIH/R01	PI	GI Regulatory Peptide Modulation of Acid Secretion.
	1991-1992	SmithKline Beecham	PI	Effects of H ₂ -antagonists on Cardiac Performance.
	1991-1993	NIH/P30	PI (pilot study)	Regulation of Gastric Inhibitory Peptide Biosynthesis.
	1989-1994	NIH/P30	Core Co-Director (Immunology)	Structure-Function Relationships in the Alimentary Tract.
	1993-1994	Glaxo Research Institute	PI	Effects of Aging on the Trophic Effects of Achlorhydria-Induced Hypergastrinemia
	1993-1995	Takeda	PI	Phase I Safety Study of Fibroblast Growth Factor in Patients with Gastroduodenal Ulcer Disease
	1995-1999	NIH/R01	PI	Regulation of the Gastric Inhibitory Peptide Gene
	1995-2000	Glaxo, Inc.	PI	Molecular Characterization of the GIP Receptor
	2001-2002	Wyeth-Ayerst	PI	Intravenous Pantoprazole in the Management of Gastrointestinal

Hemorrhage Due to Duodenal Ulcer

1997-2002	NIH/R01	PI	Definition of the Physiological Properties of GIP
2001-2003	Merck MSG	PI	Effects of COX-2 Inhibition on Metastasis of Colorectal Cancer
2003-2005	Wyeth Consumer Group		Effects of ibuprofen on Metastasis of Colorectal Cancer
2003-2008	NIH/R01	PI	Definition of the Physiological Properties of GIP
2004-2008	AstraZeneca	PI	Role of Gastrin in Pathogenesis of Esophageal Adenocarcinoma
2006-2009	NIH/R01	PI	Role of Gastrin in the Pathogenesis of Colorectal Cancer
<u>Current:</u>	2008-2011	Hartwell Foundation	PI Peptide Replacement Therapy Using Transgenic Stem Cells Delivered to the Small Intestinal Mucosa

Intellectual Property:

Patents Issued:

1. 5,229,137 *"Methods and Pharmaceutical Composition for Treating Episodic Heartburn"*; issued 7/20/93; product presently on the market - *Pepcid Complete*®
2. 7,091,183 *"Specific Antagonists for Glucose-Dependent Insulinotropic Polypeptide (GIP)"*

Patents pending:

1. 20040029805 *"Prevention and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) by Antagonism to the Receptor to Glucose-Dependent Insulinotropic Polypeptide (GIP)"*
2. 20030157071 *"Treatment or Replacement Therapy Using Transgenic Stem Cells Delivered to the Gut"*

Self Report of Teaching:

Local Contributions

UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE, Gainesville, FL

1981-1983 **Physical Diagnosis**

Group Leader
4-6 medical students
5-30 hours/year

1982-1985 **Gastroenterology Division Seminars (research and clinical)**

Presenter
20-30 GI fellows, staff, and basic scientists; 3-6 students, 0-2 interns,
0-1 resident

SHANDS HOSPITAL, Gainesville FL

1982-1985 **Gastroenterology Consult Service and General Medicine Attending**

Consult and Ward Attending
0-3 medical students; 0-2 interns; 0-1 resident; 0-1 fellow
1-2 months/year

1983-1985 **Medical Grand Rounds**

"Hepatic Encephalopathy"; "New Forms of Treatment of Peptic Ulcer"

GAINESVILLE VETERANS ADMINISTRATION HOSPITAL, Gainesville, FL

1982-1985 **Gastroenterology Consult Service Attending**

Consult Attending
0-3 medical students; 1 fellow
1 month/year

HARVARD MEDICAL SCHOOL, Boston, MA

1986-1989 **Introduction to Clinical Medicine**

Preceptor for examination of GI patient; group leader
4-6 students in both roles
2 hours/year as preceptor; 20-25 hours/year as group leader

1986-1988 **Gastrointestinal Pathophysiology (Traditional Pathway)**

Lecturer, "Peptic Ulcer Disease"
160 students
1 hour/year

1986-95 **Gastrointestinal Pathophysiology (HST-120)**

Lecturer, "Gastrointestinal Regulatory Peptides"
20-30 students

- 1 hour/year
- 1992-94 **Gastrointestinal Pathophysiology (New Pathway)**
Tutor
6-7 students
12-16 hours/year
- 1992-96 **Gastrointestinal Pharmacology & Clinical Therapeutics (HST-350)**
Lecturer
50-60 students (fourth year)
1 hour/year
- 1986-96 **Harvard Update in Gastroenterology**
"Rational Treatment of Acid-Peptic Disorders"; "Somatostatin Therapy – For Whom?"
- 1994- **Harvard Course on Infectious Disease of Adults**
"*Helicobacter pylori* and peptic ulcer disease"

BETH ISRAEL HOSPITAL, Boston, MA

- 1986-1989 **Gastroenterology Consult Service and General Medicine Attending**
Consult and Ward Attending
0-3 medical students; 0-2 interns; 0-2 resident; 2-3 fellows
2 months/year
- 1986,1988 **Medical Grand Rounds**
"Hepatic Encephalopathy"; "Therapy of Acid-Peptic Disorders"
- 1986-1989 **Intensive Review of Internal Medicine, Department of Medicine**
"Acid-Peptic Disorders"

BRIGHAM AND WOMEN'S HOSPITAL, Boston, MA

- 1986-1989 **Gastroenterology Consult Service and General Medicine Attending**
Consult and Ward Attending
0-3 medical students; 0-2 interns; 0-2 resident; 2-3 fellows
2 months/year
- 1989-96 **Intensive Review of Internal Medicine, Department of Medicine**
"Acid-Peptic Disorders"
- 1989-96 **An Internal Medicine Update for the Practicing Physician**
"Acid-Peptic Disorders"
- 1995 **Medical Grand Rounds**

“Treatment of Peptic Ulcer: Past, Present, and Future”

BOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, MA

- 1996-2000 **Gastrointestinal Pathophysiology (Biology of Disease)**
Lecturer, "GI Peptides and Neuroendocrine Tumors"
160 students
1.0 hour/year
- 1997- **Clinical Correlations**
Lecture, "Acid-Peptic Disorders"
160 students
1.0 hours/year
- 1997- **Gastrointestinal Pathophysiology (Biology of Disease)**
Lecturer, "Peptic Ulcer Disease"
160 students
1.0 hour/year
- 1997- **Gastrointestinal Pathophysiology (Biology of Disease)**
Group Discussion, "Peptic Ulcer Disease" and "Esophageal Disorders"
15-20 students
4.0 hour/year
- 1998-2001 **Department of Pharmacology Graduate Seminars**
Seminar, "Pharmacology of Acid Secretion"
6-8 graduate students
2.0 hours/year
- 2000-2002 **Molecular Medicine**
Lecture, "Molecular and Cellular Biology of Peptic Ulcer Disease"
5 graduate students
2.0 hours/year
- 2002- **Molecular Medicine**
Lecture, "Physiological and Pathologic Significance of Gastrin"
3.0 hours/year
- 2002-2005 **PhD Advisor**
Albert J. Chang, Ph.D.
Thesis: "Gastrin stimulation of colorectal cancer cell proliferation is mediated in part by attenuation of peroxisome proliferator activated receptor gamma (PPAR) activity and proteasomal degradation of PPAR γ protein"
3.0 hours/week
- 2004-2006 **PhD Thesis Committee**

Marganit Farago , Ph.D.
Thesis: "The Role of the Serine/threonine Kinases Glycogen Synthase Kinase-3 Beta and Protein Kinase CK2 in Mammary Tumorigenesis and Epithelial to Mesenchymal Transition
15.0 hours/year

2005- **Molecular Medicine**
Lecture, "Obesity, Incretins, and the GI Tract: You Are What You Eat"
3.0 hours/year

2006-2009 **PhD Advisor**
Michelle Musson, PhD
Thesis: "Evolutionary Expression of Glucose-Dependent Insulinotropic Polypeptide (GIP)"
4.0 hours/week

BOSTON MEDICAL CENTER, Boston, MA

1996- **Gastroenterology Consult Service and General Medicine Attending**
Consult and Ward Attending
1-3 medical students; 0-2 interns; 0-2 resident; 1-2 fellows
2-2.5 months/year

1996 **Medical Grand Rounds**
"Treatment of Peptic Ulcer: Past, Present, and Future"

1998 **Medical Grand Rounds**
"NSAIDs and the GI Tract: The Double-Edged Sword"

2001 **Medical Grand Rounds**
"Treatment of GERD: Extinguishing the Fire Inside"

2004 **Medical Grand Rounds**
"Obesity and the GI Tract: You Are What You Eat,"

2005 **Medical Grand Rounds**
"Highlights of the Year in Gastroenterology"

2007 **Medical Grand Rounds**
"Obesity, Incretins, and the GI Tract: You Are What You Eat"

2009 **Medical Grand Rounds**
"Management of Peptic Ulcer and Abdominal Pain: Is It Dyspepsia or Dyppepsia?"

2010 **Medical Grand Rounds**
Contemporary Management of Zollinger-Ellison Syndrome"

Current and Recent Advising Responsibilities

Medical Student Advisor (2 students)
Postdoctoral Fellow Advisor - 1-5 postdoctoral fellows in laboratory/year
Master's Thesis Advisor
PhD Thesis Advisor
1 graduate student

Regional, National, and International Contributions:

- | | |
|-----------|--|
| 1986 | Invited lectureship to American Pharmacy Association: "Treatment of Acid-Peptic Disorders" |
| 1986 | Invited lectureship, Korean Society of Gastroenterology; "Treatment of Acid-Peptic Disorders": Kwang Ju, South Korea |
| 1989- | Invited visiting professorships to numerous divisions of gastroenterology, both nationally and internationally; research and clinical seminars, medical grand rounds |
| 1993 | Invited speaker to symposium at annual meeting of American College of Gastroenterology: "Use of OTC H ₂ -Receptor Antagonists in the Treatment of Gastroesophageal Disorders" |
| 1994 | Invited to lead session at annual meeting of American Gastroenterological Association on "New Drug Treatments" |
| 1994-1995 | Invited to participate in the Digestive Health Initiative, a project launched by the American Gastroenterological Association and The American Society for Gastrointestinal Endoscopy to improve the public's awareness of diseases of the gastrointestinal tract; involved specifically in developing a program, and lecturing nationally, on <i>Helicobacter pylori</i> and its role in peptic ulcer disease |
| 1995 | Invited Visiting Professorship, Gastroenterological Association of Taiwan: "Treatment of Peptic Ulcer: Past, Present, and Future" and "Pathophysiology and Approach to NSAID-Induced Gastrointestinal Toxicity" |
| 1995 | Invited speaker at annual meeting of American College of Gastroenterology: "GI Hormones" |
| 1996 | Invited speaker at International Society for Rheumatic Therapy meeting, Paris, France: "Gastroprotection: An Arthritis Therapy Issue" |

- 1996 Invited faculty at joint Postgraduate Course of the American Gastroenterological Association and Sociedad Española de Patología Digestiva, Seville, Spain
- 1997 Donald Berkowitz Memorial Visiting Professor, Allegheny University School of Medicine, Philadelphia, PA
- 1997 Meet-the-Professor luncheon at Digestive Disease Week, Washington, D.C.
- 1997-1999 Invited faculty at the George Washington University Gastroenterology Board Review Course; lecture on "GI Hormone and Tumor Syndromes"; October 5, 1997; Washington, D.C.
- 1997-1999 Invited faculty at the American College of Gastroenterology Board Review Course; lecture on "GI Hormone and Tumor Syndromes"; October 31, 1997, Chicago, IL.; October 15, 1999, Phoenix, AZ.
- 1998 Invited faculty for the William Harvey Research Conference, "NSAIDs and the GI Tract: The Double-Edged Sword"; April 24, 1998; Cambridge, MA.
- 1998 Invited faculty for the XII Panamerican Conference of Rheumatology, "Reducing NSAID-Related Toxicity: Current Approaches"; June 23, 1998; Montreal, Quebec, Canada.
- 1998 Program Director for scientific conference: "Is COX-2 a Physiological Necessity? September 3-4, 1998; New York, NY.
- 1999 Chair, GERD Awareness Program (GAP), American Gastroenterological Association.
- 1999 Invited speaker to symposium at annual meeting of American College of Gastroenterology: "NSAIDs and the GI Tract"; October 15, 1999, Phoenix, AZ.
- 1999 Invited lecturer to Mideast Symposium on Arthritis and Osteoporosis; "NSAIDs and the GI Tract" and "Measurement and Relevance of COX-2"; October 29, 1999, Hurghada, Egypt.
- 1999 Invited speaker to symposium at annual meeting of American College of Physicians: "NSAIDs and the GI Tract"; October 15, 1999, Phoenix, AZ.
- 2000 Invited speaker at XXVIII Congresso Mexicano de Reumatologia: "COX-2 Selective Inhibitors: Panacea or Flash in the Pan?"; February 14, 2000, León, Mexico.
- 2000 Invited speaker to symposium at annual meeting of American Gastroenterological Association: "Advances in the Treatment of Hypersecretory Disorders"; May 19, 2000, San Diego, CA.

- 2000 Invited speaker at University Program on Rheumatology: "NSAIDs and the GI Tract"; June 2-4, 2000, Espoo, Finland.
- 2000 Invited speaker at GUT 2000: "COX II Inhibitors - The Dawn of a New Era?" and "Diagnosis and Treatment of Gastrinoma"; August 24-26, 2000, Melaka, Malaysia.
- 2001 Invited Speaker at Rheumatology Symposium: "COX-2 Inhibition: Improving GI Outcomes"; February 23-25, 2001, San Julian, Malta.
- 2001 Invited Speaker: "Diagnosis and Treatment of Gastrinoma"; February 26, 2001, Rambam Medical Center, Haifa, Israel.
- 2001 Chair - symposium at annual meeting of American Gastroenterological Association: "Advances in the Treatment of Hypersecretory Disorders"; May 20, 2001, Atlanta, GA.
- 2001 Invited speaker at Turkey Gastroenterology Congress: "COX II Inhibitors - The Dawn of a New Era?" October 28, 2001, Antalya, Turkey.
- 2002 Invited speaker at symposium: "GI Malignancies Can Be Prevented and Treated: From the Bench to the Bedside" January 16-20, 2002, Dead Sea, Israel.
- 2003 Visiting Professor, University of California, San Diego, April 1-2, 2003.
- 2003 Chair - symposium at annual meeting of American Gastroenterological Association: "Therapeutic Challenges: From Diagnosis to Long-Term Management of GERD"; May 18, 2003, Orlando, FL.
- 2003 Invited speaker, Israeli Society of Gastroenterology, "NSAIDs and the GI Tract: The Silent Epidemic," Herzeliyah, Israel, July 8, 2003.
- 2003 Guest Professor, Eli Lilly and Company, "Obesity, Incretins, and the GI Tract: You Are What You Eat," Indianapolis, IN, August 20, 2003.
- 2003 Guest Editor, *Current Opinions in Endocrinology & Diabetes*, Gastrointestinal Regulatory Peptides, February 2003..
- 2004 Jerome S. Levy, M.D. Visiting Professor, University of Arkansas, including Medical Grand Rounds: "NSAIDs and the GI Tract: The Silent Epidemic," Little Rock, AK, March 31 - April 2, 2004.
- 2004 Clinical symposium speaker, *GI Hormones and Acid Secretion: The Dark Side*; lecture entitled "Hypergastrinemia with Chronic Proton Pump Use: Are There Consequences?" Digestive Disease Week, New Orleans, LA, May 16, 2004.

- 2004 Chair, clinical symposium, *The GI Tract: You Are What You Eat*; lecture entitled “The Enteroinsular Axis and Obesity”; Digestive Disease Week, New Orleans, LA, May 17, 2004.
- 2005 Invited speaker, Joint Meeting of the American and Israeli Gastroenterological Associations, “Obesity, Incretins, and the GI Tract: You Are What You Eat,” Dead Sea, Israel, January 7, 2005.
- 2005 Medical Grand Rounds, University of Massachusetts, Worcester, MA. “Obesity, Incretins, and the GI Tract: You Are What You Eat”; March 10, 2005.
- 2005 Visiting Professor, University of Michigan. “Obesity, Incretins, and the GI Tract: You Are What You Eat”; March 21, 2005.
- 2005 Chair, Translational symposium, *Commercialization of Scientific Ideas*; Digestive Disease Week, Chicago, IL, May 15, 2005.
- 2005 American Gastroenterological Association symposium speaker, “Developing and Nurturing a Career in GI Research”; Digestive Disease Week, Chicago, IL, May 16, 2005.
- 2005 Invited faculty at the American College of Gastroenterology Board Review Course; lecture on “Gastric Secretions”; October 28, 2005, Honolulu, HI.
- 2006 Co-Chair, Symposium, *Issues Facing GI fellowship Programs*; Digestive Disease Week, Los Angeles, CA, May 21, 2006.
- 2006 Symposium speaker, “Core Curriculum”, Digestive Disease Week, Los Angeles, CA, May 21, 2006.
- 2006 Invited speaker at the 16th International Symposium on Regulatory Peptides, “Obesity, Incretins, and the GI Tract”; Hakone, Japan, September 1, 2006.
- 2006 Invited speaker at the third annual AGA Division Chief Workshop, “The Life of a Division Chief: Balancing Academic, Business, and Clinical Responsibilities While Maintaining Sanity”, Orlando, FL, November 12, 2006.
- 2006 Medical Grand Rounds, University of Rochester, Rochester, NY. “Obesity, Incretins, and the GI Tract: You Are What You Eat”; November 21, 2006.
- 2007 Guest Editor, *Current Opinions in Endocrinology, Diabetes and Obesity, Gastrointestinal Hormones*, February 2007.
- 2007 Visiting Professor, Mt. Sinai School of Medicine. “Obesity, Incretins, and

- the GI Tract: You Are What You Eat"; January 12, 2007.
- 2007 Medical Grand Rounds, Columbia University, New York, NY. "Obesity, Incretins, and the GI Tract: You Are What You Eat"; February 14, 2007.
- 2007 Invited speaker at the AGA Program Director Workshop, "Core Curriculum", San Antonio, TX, March 4, 2007.
- 2007 Symposium speaker, "Core Curriculum", Digestive Disease Week, Washington DC, May 20, 2007.
- 2007 Co-Chair, Symposium, *The Gut and Glucose Homeostasis*; Digestive Disease Week, Washington DC, May 21, 2007.
- 2007 Symposium speaker, "Pharmacological Therapy for Obesity and Appetite Control", Digestive Disease Week, Washington DC, May 22, 2007.
- 2007 Invited speaker at the 8th International Symposium on VIP, PACAP, and Related Peptides, "Obesity, Incretins, and the GI Tract"; Manchester, VT USA, September 6, 2007.
- 2007 Invited faculty at the American College of Gastroenterology Board Review Course; lecture on "Gastric Secretions"; October 12, 2007, Philadelphia, PA.
- 2008 Symposium speaker, "Issues Facing GI Fellowship Programs", Digestive Disease Week, San Diego, CA, May 19, 2008.
- 2008 Invited speaker, Israeli Gastroenterological Association, "Role of Incretins in the Pathogenesis of Obesity," Herzlia, Israel, June 17, 2008.
- 2008 Invited speaker, American College of Gastroenterology, "Neuroendocrine Tumors of the Pancreas and GI Tract"; Orlando, Florida, October 5, 2008.
- 2008 Guest Professor, Sixth People's Hospital of JiaoTong University, Shanghai, China, October 30-31, 2008.
- 2008 Medical Grand Rounds, The University of Chicago, Chicago, IL. "Obesity, Incretins, and the GI Tract: You Are What You Eat"; December 16, 2008.
- 2009 Symposium speaker, "Issues Facing GI Fellowship Programs", Digestive Disease Week, Chicago, IL, May 31, 2009.
- 2009 Symposium Speaker, AGMD 2009 Digestive Motility Symposium, Bedford, MA. "GERD and Its Many Manifestations", July 17, 2009.
- 2009 Invited Speaker, U.S. Food and Drug Administration, Rockville, MD. "Nonalcoholic Fatty Liver Disease: The Result of Too Much of a Good

Thing?” October 13, 2009.

2009 Medical Grand Rounds, St. Barnabas Hospital, Livingstone, NJ.
“Management of GERD: Extinguishing the Fire Inside”, December 9,
2009.

2010 Invited Speaker, 10th OESO World Conference, “How can PPI therapy be
tailored to individual needs in a cost-effective manner?” Boston, MA,
August 30, 2010.

BIBLIOGRAPHY

Original Reports:

1. Wolfe MM. Impotence on cimetidine treatment. *N Engl J Med* 1979;300:94.
2. McGuigan JE, Wolfe MM. The secretin injection test in the diagnosis of gastrinoma. *Gastroenterology* 1980;79:1324-31.
3. Caboclo JLF, Wolfe MM, Hocking MP, McGuigan JE, Woodward ER. The effect of antrectomy on the nervous phase of gastric secretion in the dog. *Am J Surg* 1981;142:324-7.
4. McGuigan JE, Wolfe MM. Gastrin radioimmunoassay. *Clin Chem* 1982;28:368-73.
5. Hocking MP, Wolfe MM, Woodward ER, Harty RF, McGuigan JE. Portal and cephalic venous gastrin following peptone infusion in the alert dog. *Am J Surg* 1982;143:339-42.
6. Wolfe MM, Alexander RW, McGuigan JE. Extraprostatic, extraintestinal gastrinoma: effective treatment by surgery. *N Engl J Med* 1982;306:1533-6.
7. Misbin RI, Wolfe MM, Morris P, Buynitzky SJ, McGuigan JE. Uptake of vasoactive intestinal peptide (VIP) by rat liver. *Am J Physiol* 1982;243:G103-11.
8. Wolfe MM, McGuigan JE. Release of gastric inhibitory peptide following a peptone meal in the dog. *Gastroenterology* 1982;83:864-72.
9. Wolfe MM, Misbin RI, Gardner DF, McGuigan JE. Enteric release of vasoactive intestinal peptide after a peptone meal in the dog. *Regul Pep* 1983;5:103-9.
10. Wolfe MM, Hocking MP, Maico DG, McGuigan JE. Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog. *Gastroenterology* 1983;84:941-8.
11. Sninsky CA, Wolfe MM, Martin JL, et al. Myoelectric effects of vasoactive intestinal peptide on rabbit small intestine. *Am J Physiol* 1983;244:G46-51.
12. Wolfe MM, Reel GM, McGuigan JE. Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa. *J Clin Invest* 1983;72:1586-93.
13. Wolfe MM, McGuigan JE. The immunochemical characterization of gastrinlike and cholecystokininlike peptides released in response to a peptone meal. *Gastroenterology* 1984;87:323-34.
14. Doyle JW, Wolfe MM, McGuigan JE. Hepatic clearance of gastrin and cholecystokinin peptides. *Gastroenterology* 1984;87:60-8.
15. Wolfe MM, Jain DK, Reel GM, McGuigan JE. Effects of carbachol on gastrin and somatostatin release in rat antral tissue culture. *Gastroenterology* 1984;87:86-93.

16. Short GM, Wolfe MM, McGuigan JE. Pentagastrin-stimulated gastric acid secretion by the isolated perfused rat stomach. *Life Sci* 1984;34:2515-23.
17. Sninsky CA, Wolfe MM, McGuigan JE, Mathias JR. Alterations in motor function of the small intestine from intravenous and intraluminal cholecystokinin. *Am J Physiol* 1984;247:G724-8.
18. Slaff JI, Wolfe MM, Toskes PP. Elevated fasting plasma cholecystokinin levels in pancreatic exocrine impairment: evidence to support feedback regulation. *J Lab Clin Med* 1985;105:282-5.
19. Short GM, Doyle JW, Wolfe MM. Effect of antibodies to somatostatin on acid secretion and gastrin release by the isolated perfused rat stomach. *Gastroenterology* 1985;88:984-8.
20. Gardner DF, Kilberg MS, Wolfe MM, McGuigan JE, Misbin RI. Preferential binding of vasoactive intestinal peptide to hepatic nonparenchymal cells. *Am J Physiol* 1985;248:G663-9.
21. Wolfe MM, Paquet RJ, Reel GM. Specificity of commercially-available antibodies used for gastrin measurement. *J Lab Clin Med* 1985;105:417-21.
22. Wolfe MM, Jain DK, Edgerton JR. Zollinger-Ellison syndrome associated with persistently normal fasting serum gastrin concentrations. *Ann Int Med* 1985;103:215-7.
23. Short GM, Reel GM, Doyle JW, Wolfe MM. Effect of GRP on β -adrenergic stimulated gastrin and somatostatin release in the isolated rat stomach. *Am J Physiol* 1985;249:G197-2.
24. Jain DK, Wolfe MM, McGuigan JE. Functional and anatomical relationships between antral gastrin cells and gastrin-releasing peptide neurons. *Histochemistry* 1985;82:463-7.
25. Curry SH, DeVane CL, Wolfe MM. Cimetidine interaction with amitriptyline. *Eur J Pharmacol* 1985;29:429-3.
26. Wolfe MM, Reel GM. Inhibition of gastrin release by gastric inhibitory peptide mediated by somatostatin. *Am J Physiol* 1986;250:G331-5.
27. Wolfe MM, Howard JE, Kolts BE, McGuigan JE. Peptide characterization of secretin preparations. *Dig Dis Sci* 1986;31:257-64.
28. Wolfe MM, Doyle JW, McGuigan JE. Hepatic clearance of somatostatin and gastrin-releasing peptide. *Life Sci* 1987;40:335-42.
29. Wolfe MM, Short GM, McGuigan JE. β -adrenergic stimulation of gastrin release mediated by gastrin-releasing peptide in rat antral mucosa. *Regul Pep* 1987;17:133-42.
30. Vogel SB, Wolfe MM, McGuigan JE, Hawkins IF, Howard RJ, Woodward ER. Localization and resection of gastrinomas in Zollinger-Ellison syndrome. *Ann Surg* 1987;205:550-6.

31. Curry SH, Devane CL, Wolfe MM. Lack of interaction of ranitidine with amitriptyline. *Eur J Clin Pharmacol* 1987;32:317-20.
32. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome: current concepts in diagnosis and treatment. *N Engl J Med* 1987;317:1200-9.
33. Wolfe MM. Consideration for selection of parenteral H₂-receptor antagonists. *Am J Med* 1987;83(Suppl 68):82-8.
34. Curry SH, Devane CL, Wolfe MM. Hypotension and Bradycardia induced by amitriptyline in healthy volunteers. *Psychopharmacology* 1988;3:47-52.
35. Wolfe MM, Soll AH. The physiology of gastric acid secretion. *N Engl J Med* 1988; 319:1707-15.
36. Karnik PS, Monahan SJ, Wolfe MM. Inhibition of gastrin gene expression by somatostatin. *J Clin Invest* 1989;83:367-72.
37. Wolfe MM, Mailliard ME, Dunn BM, Green EP, Karnik PS. Inhibition of antral gastrin cells by peptide histidine isoleucine. *Am J Physiol* 1989;257:G328-33.
38. Wolfe MM. Diagnosis of gastrinoma: much ado about nothing? *Ann Intern Med* 1989;222:697-9.
39. Mailliard ME, Wolfe MM. The effect of specific antibodies to the neuropeptide GRP on distention-induced gastric acid secretion in the rat. *Regul Pep* 1989;26:287-96.
40. Wolfe MM, Bougoulas M, McGuigan JE. Cholecystokinin binding and degradation by isolated rat liver cells. *Regul Pep* 1990;27:27-36.
41. Karnik PS, Wolfe MM. Somatostatin stimulates gastrin mRNA turnover in dog antral mucosa. *J Biol Chem* 1990;265:2550-5.
42. Wolfe MM, Chang R, Mailliard ME, Karnik PS. The effects of peptide histidine isoleucine on antral gastrin and somatostatin. *Mol Cell Endocrinol* 1992;84:89-97.
43. Karnik PS, Dushkin H, Wolfe MM. Somatostatin inhibition of gastrin gene expression: involvement of pertussis toxin-sensitive and -insensitive pathways. *Regul Pep* 1992;38:167-77.
44. Tseng C-C, Jarboe LA, Landau SB, Williams EK, Wolfe MM. Glucose-dependent insulinotropic peptide (GIP): structure of the precursor and tissue-specific expression in the rat. *Proc Natl Acad Sci USA* 1993;90:1992-6.
45. Solomon SD, Wolff S, Jarboe LA, Wolfe MM, Lee RT. The effect of H₂-receptor antagonists on left ventricular systolic function in patients with congestive heart failure. *Amer J Cardiol* 1993;72:1163-6.

46. Tseng C-C, Jarboe LA, Wolfe MM. Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal. *Am J Physiol* 1994;266:G887-91.
47. Nompleggi DJ, Beinborn M, Roy A, Wolfe MM. The effect of recombinant cytokines on [¹⁴C] aminopyrine accumulation by isolated canine parietal cells. *J Pharmacol Exp Ther* 1994;270:440-5.
48. Lichtenberger LM, Dial EJ, Romero JJ, Lechago J, Jarboe LA, Wolfe MM. Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. *Gastroenterology* 1995;108:320-9.
49. Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Håkanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM. Effects of hypochlorhydria and hypergastrinemia on the structure and function of gastrointestinal cells. A review and analysis. *Dig Dis Sci* 1995;40:50S-62S.
50. Tseng C-C, Boylan MO, Jarboe LA, Williams EK, Sunday ME, Wolfe MM. Expression of glucose-dependent insulinotropic peptide in the rat salivary gland. *Mol Cell Endocrinol* 1995;115:13-19.
51. Tseng C-C, Boylan MO, Jarboe LA, Usdin TB, Wolfe MM. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. *Am J Physiol* 1996;270:E661-6.
52. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a specific GIP receptor antagonist. *J Clin Invest* 1996;98:2440-5.
53. Boylan MO, Jepeal LI, Jarboe LA, Wolfe MM. Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene in a mouse neuroendocrine tumor cell line. *J Biol Chem* 1997;272:17438-43.
54. Yip RG-C, Boylan MO, Kieffer TJ, Wolfe MM. GIP receptors are present and functional on adipocytes. *Endocrinology* 1998;139:4004-7.
55. Tseng C-C, Zhang X-Y, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. *Am J Physiol* 1999;276:E1049-54.
56. Boylan MO, Jepeal LI, Wolfe MM. Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene. *Peptides* 1999;20:219-228.
57. Klingensmith ME, Neville LJ, Delpire E, Wolfe MM, Soybel DI. Gastrin-mediated effects of omeprazole on rat colon mucosa. *Surgery* 1999;125:272-8.
58. Wolfe MM, Zhao K-B, Glazier KD, Jarboe LA, Tseng C-C. Regulation of glucose-dependent insulinotropic polypeptide expression by protein in the rat. *Am J Physiol* 2000; 279:G561-6.

59. Cheung AT, Dayanandan B, Lewis JT, Korbitt GS, Rajotte RV, Boylan MO, Wolfe MM, Kieffer TJ. Glucose-dependent insulin release from genetically engineered K cells. *Science* 2000;290:1959-62.
60. Barrison AF, Jarboe LA, Weinberg BM, Nimmagadda K, Sullivan LM, Wolfe MM. Use patterns of proton pump inhibitors in clinical practice. *Am J Med* 2001; 111:469-73.
61. Triadafilopoulos G, DiBaise JK, Nostrant TT, Stollman NH, Anderson PK, Wolfe MM, Rothstein RI, Wo JM, Corley DA, Patti MG, Antignano LV, Edmundowicz SA, Goff JS, Castell DO, Rabine JC, Kim MS, Utley DS. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. *Gastrointest Endosc* 2002;55:149-56.
62. Yao M, Rana B, Song DH, Wolfe MM. COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer. *Br J Cancer* 2002; 87:574-9.
63. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. *Canc Res* 2003; 63:586-92.
64. Jepeal LI, Boylan MO, Wolfe MM. Cell-specific expression of the glucose-dependent insulinotropic polypeptide (GIP) gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line. *Regul Pep* 2003; 113:139-47.
65. Song DH, Rana B, Crimmins GM, Wolfe JR, Wang TC, Pestell RG, Albanese C, Wolfe MM. Cyclin D1 mediates the trophic properties of gastrin in gastric adenocarcinoma. *Am J Physiol* 2003; 285:G217-G222.
66. Corley DA, Katz P, Wo JM, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe MM. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of gastroesophageal reflux disease: a randomized, blinded, sham-controlled trial. *Gastroenterology* 2003; 125:668-676.
67. Fisher JC, Masiakos PT, Oviedo J, Burch M, Kondi, ES, Wolfe MM, Becker JM. Gastric outlet obstruction as a consequence of a duodenal web masquerading as gastrinoma in an adult. *Curr Surg* 2003; 60:602-606.
68. Yao M, Lam EC, Kelly CR, Wolfe MM. Cyclooxygenase-2 selective inhibition suppresses proliferation, invasiveness, and liver metastasis in colorectal cancer. *Br J Cancer* 2004; 90:712-719.
69. Scheiman JM, Cryer B, Kimmey MB, Rothstein RI, Riff, DS, Wolfe MM. A randomized controlled comparison of ibuprofen at the maximal over-the-counter (OTC) dose compared to prescription dose celecoxib on upper gastrointestinal mucosal injury. *Clin Gastroenterol Hepatol* 2004;2:290-295.
70. Pradeep A, Sathyanarayana P, Albanese C, Pestell RG, Flammig E, Wang TC, Wolfe MM, Baker KM, Rana B. Gastrin mediated induction of cyclin D1 in gastric cancer cells involves the Wnt-signaling and MAP kinase pathways. *Oncogene* 2004;23:3689-3699.

71. Moore TC, Jepeal LI, Boylan MO, Singh SK, Boyd N, Beer DG, Wolfe MM. Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells. *Regul Pep.* 2004;120:195-203.
72. Jepeal LI, Fujitani Y, Boylan MO, Wilson CN, Wright CV, Wolfe MM. Cell-specific expression of glucose-dependent insulinotropic polypeptide (GIP) requires the transcription factor PDX-1. *Endocrinology* 2005;146:383-391.
73. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Wolfe MM. Non-selective COX inhibition with ibuprofen attenuates tumor growth and liver metastasis, and enhances the antitumor efficacy of chemotherapy in colorectal cancer. *Clin Canc Res* 2005;11:1618-1628.
74. Song DH, Kaufman JC, Borodyansky L, Albanese C, Pestell RG, Wolfe MM. Gastrin stabilises β -catenin protein in mouse colorectal cancer cells. *Br J Cancer* 2005;25:1581-1587.
75. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ. Proliferator-activated receptor γ inhibition prevents adhesion of the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. *Cancer Res* 2005;65:2251-2259.
76. Spina C, Tangpricha V, Yao M, Zhou W, Wolfe MM, Maehr H, Uskokovic M, Holick MF. Colon cancer and ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its gemini analogues. *J Steroid Biochem and Mol Biol* 2005;97:111-120.
77. Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, Holick MF. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. *J Nutrition* 2005;135:2350-2354.
78. Boylan MO, Jepeal LI, Wolfe MM. Sp1/Sp3 binding is associated with cell-specific expression of the glucose-dependent insulinotropic polypeptide receptor gene. *Am J Physiol* 2006; 290:E1287-E1295.
79. Chang AJ, Song DH, Wolfe MM. Gastrin stimulation of colorectal cancer cell proliferation is mediated in part by attenuation of peroxisome proliferator activated receptor gamma (PPAR γ) activity and proteasomal degradation of PPAR γ protein. *J Biol Chem* 2006; 281:14700-14710.
80. Getty-Kaushik L, Song DH, Boylan MO, Corkey B, Wolfe MM. A receptor specific antagonist reverses the insulin mimetic properties of glucose-dependent insulinotropic polypeptide (GIP) on lipolysis and triglyceride synthesis in perfused rat adipocytes. *Obesity* 2006; 14:1124-1131.
81. Spina CS, Ton L, Yao M, Maehr H, Wolfe MM, Uskokovic M, Adorini L, Holick MF. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. *J Steroid Biochem Mol Biol.* 2007;103:757-762.

82. Song DH, Getty-Kaushik L, Tseng E, Simon, J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. *Gastroenterology* 2007, 123:1796-1805.
83. Jepeal LI, Boylan MO, Wolfe MM. GATA-4 upregulates glucose-dependent insulinotropic polypeptide expression in cells of pancreatic and intestinal lineage. *Mol Cell Endocrinol* 2008;287:20-29.
84. Singh SK, Bartoo AC, Krishnan S, Boylan MO, Schwartz JH, Wolfe MM. Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport. *Obesity* 2008;16:2412-2416.
85. Goldman JA, Blanton WP, Hay DW, Wolfe MM. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. *Clin Gastroenterol Hepatol* 2009;7:600-602.
86. Musson MC, Jepeal LI, Mabray P, Zhdanova I, Cardoso W, Wolfe MM. Expression of the glucose-dependent-insulinotropic polypeptide (GIP) in the zebrafish. *Am J Physiol Regul Integr Comp Physiol*. 2009;297:R1803-R1812.
87. Prabakaran D, Wang B, Feuerstein JD, Sinclair S, Wolfe MM. Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells. *Regul Pep* 2010, In Press.
88. Musson MC, Jepeal LI, Sharifnia T, Wolfe MM. Evolutionary conservation of glucose-dependent insulinotropic polypeptide (GIP) gene regulation and the enteroinsular axis. *Regul Pep* 2010, In Press.
89. Musson MC, Jepeal LI, Finnerty JR, Wolfe MM. Evolutionary expression of the glucose-dependent insulinotropic polypeptide (GIP). Submitted for publication.
90. Lew EA, Cook NR, Blaser MJ, Perez-Perez G, Stampfer MJ, Wolfe MM, Gaziano JM. Interactions between *Helicobacter pylori* and nonsteroidal anti-inflammatory drugs affect long-term risk of peptic ulcer disease. Submitted for publication.

Book Chapters and Monographs:

1. McGuigan JE, Wolfe MM. Radioimmunoassay of gastrin. In: Forman DT, ed. *Selected Methods of Clinical Chemistry*. Washington, D.C.: American Association for Clinical Chemistry, 1983:116-21.
2. McGuigan JE, Wolfe MM. Anorexia, nausea and vomiting. In: Blacklow RS, ed. *Signs and Symptoms*, 6th Edition. Philadelphia: JP Lippincott, 1983:361-73.
3. Wolfe MM, McGuigan JE. Islet cell tumors and the ulcerogenic syndrome. In: Volk B et al., eds. *The Diabetic Pancreas*. New York: Plenum Publishing Co., 1985:587-615.
4. Wolfe MM. Acid-Peptic Disease. In: Braunwald E and Fanta CH, eds. *Intensive Review of Internal Medicine*, 3rd edition. Boston: Nimrod Press, 1988:426-37.
5. Seeling MS, Wolfe MM. Other clinical situations of magnesium deficiencies. In: Giles JD and Seeling MS, eds. *The Role of Magnesium Chloride Therapy in Clinical Practice* (Monograph). Clifton, NJ: Oxford Health Care, Inc., 1988:17-8.
6. Wolfe MM. Endocrinology of the GI tract. In: Chopra S and May RJ, eds. *Pathophysiology of Gastrointestinal Diseases*. Boston: Little, Brown, and Company, 1989:573-98.
7. Van Dam J, Wolfe MM. Zollinger-Ellison syndrome: pathogenesis and diagnosis. In: Landor J, ed. *Problems in General Surgery*. Philadelphia: Lippincott, 1990; 7:500-20.
8. Berg C, Wolfe MM. Zollinger-Ellison syndrome. In: Katz J, ed. *Peptic Ulcer Disease/Medical Clinics of North America*. Philadelphia: W.B. Saunders Company, 1991; 75:903-21.
9. Van Dam J, Wolfe MM. Gastrin and other peptide hormones. In: Collen MJ and Benjamin SB, eds. *Pharmacology of Peptic Ulcer Diseases*. Heidelberg: Springer-Verlag, 1991:55-88.
10. Nompleggi DJ, Wolfe MM. Peptic ulcer disease - pathogenesis and treatment. In: Zakim D and Dannenberg A, eds. *Ulcer Disease in the Modern Era*. New York: Cornell University Press, 1991:33-66.
11. Lichtenstein DR, Berman MD, Wolfe MM. Approach to the patient with upper gastrointestinal hemorrhage. In: Taylor MB et al., eds. *Gastrointestinal Emergencies*. Baltimore: Williams and Wilkins, 1992:92-116.
12. Lichtenstein DR, Wolfe MM. Histamine H₂-receptor antagonists. In: Wolfe MM, ed. *Gastrointestinal Pharmacotherapy*. Philadelphia: W.B. Saunders Company, 1993:47-84.
13. Wolfe MM. Stress-related erosive syndrome. In: Bayless TM, ed. *Current Therapy in Gastroenterology and Liver Disease*. Philadelphia: Moseby-Year Book, Inc., 1994:139-43.

14. Lichtenstein DR, Berman MD, Wolfe MM. Approach to the patient with upper gastrointestinal hemorrhage. In: Taylor MB et al., eds. *Gastrointestinal Emergencies*, Second Edition. Baltimore: Williams and Wilkins, 1997;99-129.
15. Slivka A, Wolfe MM. Lower gastrointestinal hemorrhage. In: Taylor MB et al., eds. *Gastrointestinal Emergencies*, Second Edition. Baltimore: Williams and Wilkins, 1997;493-513.
16. Tseng C-T, Wolfe MM. Management of non-steroidal anti-inflammatory drug-related gastrointestinal mucosal injury. In Vane J and Botting R, eds. *Clinical Significance and Potential of Selective COX-2 Inhibitors*. London: William Harvey Press, 1998, 85-98.
17. Stefan A, Wolfe MM. Duodenal ulcer. In Brandt LJ, ed. *Clinical Practice of Gastroenterology*. Philadelphia: Current Medicine, Inc., 1999, 273-81.
18. Wolfe MM, Boylan MO, Kieffer TJ, Tseng C-T. Glucose-dependent insulinotropic polypeptide (GIP): Incretin vs. enterogastrone. In Conn MP, ed. *Gastrointestinal Endocrinology*. Totowa, NJ: Humana Press, 1999, 439-66.
19. Wolfe MM. Therapy and prevention of NSAID-related gastrointestinal disorders. In Wolfe MM, ed. *Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran Gastrointestinal Diseases*. Philadelphia: W.B. Saunders Company, 2000, 96-112.
20. Lowe RC, Wolfe MM. Acid peptic disorders, gastritis, and *Helicobacter pylori*. In Noble J, Ed. *Textbook of Primary Care Medicine, third edition*. St. Louis, MO: Mosby, Inc., 2000, 910-20.
21. Oviedo JA, Wolfe MM. Erosive Esophagitis. In Fass R Ed., *Hot Topics in GERD and Dyspepsia*, 2003, 83-99.
22. Tseng C-C, Wolfe MM. Glucose-dependent insulinotropic polypeptide. In *Encyclopedia of Gastroenterology*, San Diego: Academic Press/Elsevier Science, 2003.
23. Bliss CM, Wolfe MM. Abdominal pain. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, sixth edition*. Philadelphia: W.B. Saunders Company, 2004, 313-316.
24. Tseng C-C, Wolfe MM. Gastrointestinal hemorrhage. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, sixth edition*. Philadelphia: W.B. Saunders Company, 2004, 317-320.
25. Jacobson BC, Wolfe MM. Endoscopic and Radiographic procedures in gastroenterology. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, sixth edition*. Philadelphia: W.B. Saunders Company, 2004, 333-339.
26. Lowe RC, Wolfe MM. Diseases of the esophagus. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, sixth edition*. Philadelphia: W.B. Saunders Company, 2004, 341-346.

27. Oviedo JA, Wolfe MM. Diseases of the stomach and duodenum. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, sixth edition*. Philadelphia: W.B. Saunders Company, 2004, 347-362.
28. Song DH, Bowdish EA, Rana B, Wolfe JR, Wolfe MM. Gastrin and cell growth. Merchant J et al., Eds. *Gastrin in the New Millenium*, CURE Foundation 2004, 299-310.
29. Oviedo JA, Wolfe MM. Treatment of gastric ulcers with PPIs. In Scarpignato C & Sachs G, Eds. *Proton Pump Inhibitors: From Molecular Biology to Clinical Practice*. Basel, Switzerland: S. KARGER Medical and Scientific Publishers, 2005, In Press.
30. Oviedo JA, Wolfe MM. Management of stress-related erosive syndrome. In: Bayless TM and Diehl AM, eds. *Current Therapy in Gastroenterology and Liver Disease, fifth edition*. Hamilton, Ontario: BC Decker, Inc., 2005, 161-166.
31. Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In Wolfe MM and Lowe RC, eds. *Educational Review Manual in Gastroenterology*. New York: Castle-Connolly Graduate Medical Publishing, 2005, 1-31.
32. Oviedo JA, Wolfe MM. Therapy and prevention of NSAID-related gastrointestinal disorders. In Wolfe MM, ed. *Therapy of Digestive Disorders*. New York: Elsevier, 2006, 291-314.
33. Lowe RC, Lundell L, Rothstein RI, Wolfe MM. Gastroesophageal reflux disease. In Wolfe MM, ed. *Therapy of Digestive Disorders*. New York: Elsevier, 2006, 191-208.
34. Wolfe MM, Simon JT, Lowe RC. Peptic ulcer disease. In Parkman HP and Fisher RS, Eds., *The Clinician's Guide to Acid/Peptic Disorders and Motility Disorders of the Gastrointestinal Tract*. Thorofare, NJ: Slack, Inc., 2006, 115-149.
35. Bliss CM, Wolfe MM. Abdominal pain. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, seventh edition*. New York: Elsevier, 2007, 357-360.
36. Tseng C-C, Wolfe MM. Gastrointestinal hemorrhage. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, seventh edition*. New York: Elsevier, 2007, 360-364.
37. Lowe RC, Wolfe MM. Diseases of the esophagus. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, seventh edition*. New York: Elsevier, 2007, 384-389.
38. Oviedo JA, Wolfe MM. Diseases of the stomach and duodenum. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, seventh edition*. New York: Elsevier, 2007, 390-405.
39. Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In Wolfe MM and Lowe RC, eds. *Educational Review Manual in Gastroenterology*. New York: Castle-Connolly Graduate Medical Publishing, 2007, 417-449.
40. Bliss CM, Wolfe MM. Abdominal pain. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, eighth edition*. New York: Elsevier, 2010, 382-385.

41. Moore TC, Tseng C-C, Wolfe MM. Gastrointestinal hemorrhage. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, eighth edition*. New York: Elsevier, 2010, 385-388.
42. Lowe RC, Wolfe MM. Diseases of the esophagus. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, eighth edition*. New York: Elsevier, 2010, 408-413.
43. Blanton WP, Oviedo JA, Wolfe MM. Diseases of the stomach and duodenum. In Andreoli TE et al., Eds. *Cecil Essentials of Medicine, eighth edition*. New York: Elsevier, 2010, 414-429.
44. Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In Wolfe MM and Lowe RC, eds. *Educational Review Manual in Gastroenterology*. New York: Castle-Connolly Graduate Medical Publishing, 2010, In Press.

Summaries and Reviews:

1. Wolfe MM. Localization of gastrinoma using arterial secretin stimulation - worthwhile or passing fancy? *Gastroenterology* 1991;100:1472-4.
2. Wolfe MM. At long last - the histamine H₂-receptor gene is cloned. *Gastroenterology* 1991;101:554-5.
3. Wolfe MM. H₂-antagonists by continuous infusion: IV or IG? *Gastroenterology* 1991;101:1448-9.
4. Wolfe MM. Gastrin is a potent stimulant of the parietal cell -- maybe. *Gastroenterology* 1992;102:365-7.
5. Wolfe MM, Nompleggi DJ. Cytokine inhibition of gastric acid secretion -- a little goes a long way. *Gastroenterology* 1992;102:2177-8.
6. Wolfe MM. Hypergastrinemia and colorectal neoplasia -- coincidental or related? *Gastroenterology* 1992;103:1361-3.
7. Wolfe MM. What is intensive therapy for gastroesophageal reflux? *Gastroenterology* 1992;103:1696-8.
8. Van Dam J, Wolfe MM. Pancreatic endocrine tumors - seek and ye shall find. *Gastroenterology* 1992;103:1982-4.
9. Van Dam J, Wolfe MM. Zollinger-Ellison syndrome. *Seminars in Gastrointestinal Disease* 1993;4:47-59.
10. Wolfe MM, Tseng C-C. The gastrin (or is it CCK-B?) receptor is cloned. *Gastroenterology* 1993;104:1876-8.
11. Wolfe MM. ECL cells: The controller in oxyntic mucosa. *Gastroenterology* 1993;105:602-4.
12. Boylan MO, Wolfe MM. Colorectal carcinogenesis: looking for the lost genes. *Gastroenterology* 1993; 105:1579-82.
13. Wolfe MM. Pathophysiology and clinical implications of gastroesophageal reflux disease. *Prac Gastroenterol* 1994; 18:S10-6.
14. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: The double-edged sword. *Arth Rheum* 1995; 38:5-18.
15. Wolfe MM. NSAIDs and the gastrointestinal mucosa. *Hosp Prac* 1996; 31:37-48.
16. Syngal S, Wolfe MM, Friedman LS, Van Dam J. *Helicobacter pylori*: Pathogenic factor in the etiology of gastrointestinal diseases. *Infect Dis Clin Prac* 1997;6:17-27.
17. Wolfe MM (Guest Editor). Introduction: NSAID-associated GI toxicity. *Amer J Med* 1998;105(5A):1S-2S.

18. Wolfe MM. Future trends in the development of safer nonsteroidal anti-inflammatory drugs. *Amer J Med* 1998;105(5A):44S-52S.
19. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N Engl J Med* 1999;340:1888-1899.
20. Beejay U, Wolfe MM. COX-2 selective inhibitors: Panacea or flash in the pan? *Gastroenterology* 1999;117:1002-1005.
21. Yip RGC, Wolfe MM. GIP Biology and Fat Metabolism. *Life Sci* 1999;66:91-103.
22. Barrison AF, Wolfe MM. Management of NSAID-related gastrointestinal mucosal injury. *Inflammapharmacology* 1999;7:277-286.
23. Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. *Gastroenterology* 2000;118:S9-S31.
24. Beejay U, Wolfe MM. Gastrointestinal bleeding in the intensive care unit. *Gastro Clin N Amer* 2000;29:309-336.
25. Lichtenstein DR, Wolfe MM. COX-2 selective NSAIDs: New and improved. *JAMA* 2000;284:1297-1299.
26. Tseng C-C, Wolfe MM. Nonsteroidal antiinflammatory drugs. *Med Clin N Am* 2000;84:1329-1344.
27. Stone CD, Beejay U, Wolfe MM. Image of the month. Pheochromocytoma. *Gastroenterology* 2001;120:326.
28. Oviedo JA, Wolfe MM. Clinical potential of cyclo-oxygenase-2 inhibitors. *BioDrugs* 2001;15:563-572.
29. Wolfe MM, Welage LS, Sachs G. Proton pump inhibitors and gastric acid secretion. *Am J Gastroenterol* 2001;96:3467-3468.
30. Wolfe MM. Diagnosis and management of Zollinger-Ellison syndrome. *Prac Gastroenterol* 2002;26:15-32.
31. Oviedo JO, Wolfe MM. Alcohol, acetaminophen, and toxic effects on the liver. *Arch Intern Med* 2002;162:1194-1195.
32. Wolfe MM. Gastrointestinal regulatory peptides. *Current Opinions in Endocrinology & Diabetes* 2003; 10:37-38.
33. Wolfe MM, Song DH, Jepeal JI, Moore TC. Gastrin peptides: Pathophysiological role in gastrointestinal carcinogenesis. *Current Opinions in Endocrinology & Diabetes* 2003; 10:39-49.
34. Wolfe MM. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. *Int J Clin Prac* 2003;Suppl 135:32-37.

35. Wolfe MM (Guest Editor). Pharmacological principles governing the use of proton pump inhibitors: Tailoring therapy to improve GERD outcomes. *Gastroenterol Clin N Am* 2003;32:VII-IX.
36. Wolfe MM. Managing gastroesophageal reflux disease: From pharmacology to the clinical arena. *Gastroenterol Clin N Am* 2003;32:S37-S46.
37. Oviedo JA, Wolfe MM. Gastroprotection from coxibs: What do the CLASS and VIGOR trials tell us? *Rheum Clin N Amer* 2003; 29:769-788.
38. McGuigan JE, Belafsky PC, Fromer L, McCarthy D, Nostrant T, Postma GN, Welage LS, Wolfe MM. Review article: diagnosis and management of night-time reflux. *Aliment Pharmacol Ther* 2004;20 Suppl 9:57-72.
39. Lowe RC, Wolfe MM. The pharmacological management of gastroesophageal reflux disease. *Minerva Gastroenterol Dietol* 2004;50:227-237.
40. McGuigan JE, Belafsky PC, Fromer L, McCarthy D, Nostrant T, Postma GN, Welage LS, Wolfe MM. Review article: diagnosis and management of night-time reflux. *Aliment Pharmacol Ther* 2004;20 Suppl 9:57-72.
41. Wolfe MM. Rofecoxib, Merck, and the FDA. *N Engl J Med* 2004; 30;351(27):2875-2878.
42. Sangha S, Yao M, Wolfe MM. Nonsteroidal anti-inflammatory drugs and colorectal cancer prevention. *Postgrad Med J* 2005;81:223-227.
43. Wolfe MM. Gastrointestinal regulatory peptides: an overview. *Current Opinions in Endocrinology Diabetes and Obesity* 2007;14:41-45.
44. Song DH, Wolfe MM. Glucose-dependent insulinotropic polypeptide and its role in obesity. *Current Opinions in Endocrinology, Diabetes and Obesity* 2007;14:46-51.
45. Wolfe MM, Lowe RC. Investing in the Future of GERD. *J Clin Gastroenterol* 2007;41:S209-S216.

Books:

1. Taylor MB, Gollan JL, Peppercorn MA, Steer ML, Wolfe MM, eds. *Gastrointestinal Emergencies*. Baltimore: Williams and Wilkins, 1992.
2. Wolfe MM, ed. *Gastrointestinal Pharmacotherapy*. Philadelphia: W.B. Saunders Company, 1993.
3. Wolfe MM, Nesi TJ. *The Fire Inside*. New York: W.W. Norton and Company, 1996.
4. Taylor MB, Gollan JL, Steer ML, Wolfe MM, eds. *Gastrointestinal Emergencies*, Second Edition, Baltimore: Williams and Wilkins, 1997.
5. Wolfe MM, Nesi TJ. *Heartburn: Extinguishing The Fire Inside*. New York: W.W. Norton and Company, 1997.
6. Wolfe MM, ed. *Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran Gastrointestinal Diseases*. Philadelphia: W.B. Saunders Company, 2000.
7. Wolfe MM and Lowe RC, eds. *Educational Review Manual in Gastroenterology*. New York: Castle-Connolly Graduate Medical Publishing, 2005.
8. Wolfe MM, ed. *Therapy of Digestive Disorders, 2nd Edition*. New York: Elsevier, 2006.
9. Wolfe MM and Lowe RC, eds. *Educational Review Manual in Gastroenterology*. New York: Castle-Connolly Graduate Medical Publishing, 2007.
10. Wolfe MM and Lowe RC, eds. *Educational Review Manual in Gastroenterology*. New York: Castle-Connolly Graduate Medical Publishing, 2010, In Press.

Abstracts:

1. Mayle JE, Wolfe MM, Caldwell JH, O'Dorisio TM, Cataland S, Thomas FB. Gastric emptying and serum gastric inhibitory polypeptide (GIP) after oral glucose. *Gastroenterology*. 1978;74:1063.
2. Wolfe MM, Hocking MP, Harty RF, Woodward ER, McGuigan JE. Meal-stimulated biphasic gastrin release into the portal and peripheral circulation. *Clin Res*. 1980;28:486A.
3. Wolfe MM, McGuigan JE. Meal-stimulated vasoactive intestinal peptide release in the dog. *Gastroenterology*. 1980;78:1294.
4. Wolfe MM, McGuigan JE. Immunochemical definition of gastrin-like peptides released in response to a peptone meal. *Gastroenterology*. 1980;78:1294.
5. Wolfe MM, McGuigan JE. Release of gastric inhibitory peptide following a peptone meal in the dog. *Clin Res*. 1981;29:511A.
6. Sninsky CA, Martin JL, Wolfe MM, McGuigan JE, Mathias JR. Do gut peptides work solely through an endocrine mechanism? Alterations of intestinal motility after luminal infusion of cholecystokinin. *Clin Res*. 1981;29:312A.
7. Sninsky C, Martin J, Wolfe MM, et al. Diarrhea genic motor complex induced by intravenous and intraluminal vasoactive intestinal peptide. *Gastroenterology*. 1981;80:1289.
8. Wolfe MM, Hocking MP, Maico DG, McGuigan JE. Gastric inhibitory peptide is an enterogastrone. *Gastroenterology*. 1981;80:1318.
9. Wolfe MM, Kolts BE, McGuigan JE. Multiple gastrointestinal peptides in Boots secretin. *Gastroenterology*. 1981;80:1318.
10. Misbin RI, Wolfe MM, Morris P, Buynitzky SJ, McGuigan JE. Vasoactive intestinal peptide uptake, binding and degradation by isolated rat hepatocytes. *Clin Res*. 1982;30:497A.
11. Wolfe MM, Alexander RW, McGuigan JE. Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery. *Gastroenterology*. 1982;82:1212.
12. Wolfe MM, Misbin RI, Morris P, Buynitzky SJ, McGuigan JE. Hepatic uptake and degradation of vasoactive intestinal peptide. *Gastroenterology*. 1982;82:1212.
13. Wolfe MM, Kolts BE, McGuigan JE. Relative immunochemical purity of GIH and Boots secretin. *Gastroenterology*. 1982;82:1212.
14. Wolfe MM, Reel GM, McGuigan JE. Effects of carbachol on gastrin and somatostatin release in rat antral tissue culture. *Clin Res*. 1983;31:477A.
15. Doyle JW, Wolfe MM, McGuigan JE. Hepatic degradation of gastrin-like peptides. *Gastroenterology*. 1983;84:1140.

16. Wolfe MM, McGuigan JE. Release of cholecystokinin-like peptides following peptone meal stimulation in the dog. *Gastroenterology*. 1983;84:1353.
17. Wolfe MM, McGuigan JE. Molecular forms of gastrin released into the portal vein following a peptone meal in the dog. *Gastroenterology*. 1983;84:1353.
18. Wolfe MM, Reel GM, McGuigan JE. Inhibition of gastrin release by secretin mediated by somatostatin. *Gastroenterology*. 1983;84:1353.
19. Wolfe MM, Harty RF, McGuigan JE. The effect of gastric inhibitory peptide on gastrin release and gastric acid secretion in the dog. *Regul Pep Suppl*. 1983;2:S15.
20. Wolfe MM, Misbin RI, Harty RF, McGuigan JE. Enteric release and hepatic degradation of vasoactive intestinal peptide. *Regul Pep Suppl*. 1983; 2:S49-50.
21. Harty RF, Franklin PA, Wolfe MM, McGuigan JE. The effects of gamma-aminobutyric acid on gastrin and somatostatin release from isolated rat antral mucosa. *Regul Pep Suppl*. 1983;2:S113-114.
22. Gardner DF, Kilberg MS, McGuigan JE, Wolfe MM, Misbin RI. Preferential binding of vasoactive intestinal peptide to hepatic nonparenchymal cells. *Clin Res*. 1984; 32:281A.
23. Short GM, Wolfe MM, McGuigan JE. Pentagastrin-stimulated gastric acid secretion by the isolated perfused rat stomach. *Clin Res*. 1984;32:491A.
24. Slaff JI, Wolfe MM, McGuigan JE, DesJardin L, Toskes PP. A sensitive tubeless pancreatic function test. *Clin Res*. 1984;32:491A.
25. Wolfe MM, Reel GM, Short GM, McGuigan JE. Beta-adrenergic stimulation of gastrin release mediated by gastrin-releasing peptide in cultured rat antral mucosa. *Gastroenterology*. 1984;86:1301.
26. Wolfe MM, Reel GM, McGuigan JE. Inhibition of gastrin release by gastric inhibitory peptide mediated by somatostatin in rat antral tissue culture. *Gastroenterology*. 1984; 86:1300.
27. Doyle JW, Wolfe MM, McGuigan JE. Hepatic degradation of cholecystokinin. *Gastroenterology*. 1984;86:1065.
28. Short GM, Wolfe MM, Doyle JW, McGuigan JE. Effect of somatostatin on acid secretion and gastrin release in the isolated perfused rat stomach. *Gastroenterology*. 1984;86:1250.
29. Wolfe MM, Short GM, Reel GM, McGuigan JE. Effect of gastrin-releasing peptide on acid secretion and gastrin release in the isolated rat stomach. *Gastroenterology*. 1984; 86:1301.
30. Slaff JI, Wolfe MM, McGuigan JE, DesJardin LE, Toskes PP. Hormonal mediation of pancreatic exocrine secretion by intraduodenal proteases in patients with chronic pancreatitis. *Gastroenterology*. 1984;86:1255.

31. Slaff JI, Wolfe MM, Toskes PP. Elevated fasting plasma cholecystokinin levels in pancreatic exocrine impairment: evidence to support feedback regulation. *Gastroenterology*. 1984;86:1255.
32. Wolfe MM, Paquet RJ, Reel GM. Peptide specificity of commercially-available antibodies used for gastrin measurement. *Gastroenterology*. 1984;86:1300.
33. Wolfe MM, McGuigan JE. Effect of antibodies to gastrin-releasing peptide on beta-adrenergic stimulated gastrin release. *Dig Dis Sci*. 1984;29:96S.
34. Wolfe MM, Reel GM, McGuigan JE. Somatostatin mediation of secretin- and GIP-induced inhibition of gastrin release. *Dig Dis Sci*. 1984;29:96S.
35. Slaff JI, Wolfe MM, Toskes PP. Pancreatic extract inhibition of plasma CCK levels. *Dig Dis Sci*. 1984;29:969.
36. Bougoulas M, Wolfe MM, Kilberg MS, Misbin RI, McGuigan JE. Cholecystokinin binding by isolated rat liver cells. *Gastroenterology*. 1985;88:1712.
37. Doyle JW, Wolfe MM, McGuigan JE. Hepatic clearance of gastrointestinal paracrine/neurocrine regulatory peptides. *Gastroenterology*. 1985;88:1369.
38. Wolfe MM, Franklin PA, Mailliard ME. Peptide histidine isoleucine inhibits carbachol-stimulated gastrin release in cultured rat antral mucosa. *Gastroenterology*. 1985;88:1634.
39. Fleet SB, Franklin PA, Reel GM, Wolfe MM. Vasoactive intestinal peptide inhibits gastrin release in cultured rat antral mucosa. *Gastroenterology*. 1985;88:1384.
40. Mailliard ME, Doyle JW, Reel GM, Wolfe MM. Effect of gastrin-releasing peptide on distention-induced gastric acid secretion and gastrin release. *Gastroenterology*. 1985;88:1487.
41. Curry SH, DeVane CL, Wolfe MM. Cimetidine interaction with amitriptyline. *Gastroenterology*. 1985;88:1358.
42. Slaff JI, Wolfe MM, Toskes PP. Acute and chronic inhibition of plasma cholecystokinin (CCK) levels by pancreatic proteases. *Gastroenterology*. 1985;88:1590.
43. Wolfe MM, Mailliard ME. Direct inhibition of gastrin release by peptide histidine isoleucine in rat antral mucosa. *Gastroenterology*. 1986;90:1694.
44. Mailliard ME, Wolfe MM. Effect of gastrin-releasing peptide (GRP) on distention-induced acid secretion. *Gastroenterology*. 1986;90:1530.
45. Karnik PS, Monahan SJ, Wolfe MM. Regulation of gastrin messenger RNA by somatostatin in dog antral mucosa. *Gastroenterology*. 1987;92:1460.

46. Karnik PS, Wolfe MM. Somatostatin inhibition of gastrin mRNA transcription in dog antral mucosa. *Gastroenterology*. 1988; 94:A217.
47. Karnik PS, Wolfe MM. Peptide histidine isoleucine inhibits antral gastrin cells at the pretranslational level. *Gastroenterology*. 1988;94:A217.
48. Karnik PS, Lichtenstein DR, Wolfe MM. Somatostatin inhibits gastrin gene expression via cAMP and calcium-dependent pathways. *Gastroenterology*. 1989;96:A249.
49. Karnik PS, Wolfe MM. Somatostatin enhances gastrin mRNA turnover in dog antral mucosa. *Gastroenterology*. 1989;96:A249.
50. Wolfe MM, Nishitani J, Dushkin H, Nompleggi DJ, Karnik PS. Inhibition of gastrin gene expression by somatostatin involves both cAMP- and calcium-dependent pathways. *Clin Res*. 1990;38:423A.
51. Nompleggi DJ, Nishitani J, Dushkin H, Wolfe MM. Prosomatostatin-derived antrin inhibits gastrin gene expression in canine antral mucosa. *Gastroenterology*. 1990; 98:A515.
52. Geoghegan JG, Wolfe MM, Pappas TN. Antrin, a prosomatostatin cleavage product, increases meal-stimulated gastric acid. *Gastroenterology*. 1990; 98:A48.
53. Beinborn M, Nishitani J, Kromer W, Wolfe MM. Expression of muscarinic receptors in the dog gastric mucosa. *Gastroenterology*. 1991;100:A33.
54. Tseng C-C, Jarboe LA, Landau SB, Wolfe MM. Gastric inhibitory peptide (GIP): structure of an intestinal cDNA and tissue-specific gene expression in the rat. *Gastroenterology*. 1992;102:A762.
55. Lichtenberger LM, Dial EJ, Romero J, Lechago J, Jarboe LA, Wolfe MM. Alterations in gastrin homeostasis in response to chronic elevations of intraluminal ammonia. *Gastroenterology*. 1992;102:A653.
56. Nompleggi D, Beinborn M, Wolfe M. The effect of recombinant cytokines on [¹⁴C]-aminopyrine accumulation in isolated canine parietal cells. *Gastroenterology*. 1992; 102:A748.
57. Tseng C-C, Jarboe LA, Wolfe MM. Nutrient-dependent regulation of gastric inhibitory peptide gene expression in the rat. *Regul Pep*. 1992; 40:264.
58. Tseng C-C, Jarboe LA, Williams EK, Sunday ME, Wolfe MM. Expression of the gastric inhibitory peptide (GIP) gene in the rat salivary gland: ontogeny and significance. *Gastroenterology*. 1993;104:A860.
59. Tseng C-C, Jarboe LA, Wolfe MM. Nutrient-dependent regulation of gastric inhibitory peptide (GIP) gene expression in the rat. *Gastroenterology*. 1993;104:A650.

60. Wolfe MM, Bynum TE, Parsons WG, Malone KM, Szabo S, Folkman J. Safety and efficacy of an angiogenic peptide, basic fibroblast growth factor (bFGF), in the treatment of gastroduodenal ulcers: a preliminary report. *Gastroenterology*. 1994;106:A212.
61. Tseng C-C, Jarboe LA, Wolfe MM. Co-induction of glucose-dependent insulintropic peptide (GIP) and α -amidating enzyme (PAM) gene expression in diabetic rats. *Gastroenterology*. 1994;106:A846.
62. Boylan MO, Tseng C-C, Jarboe LA, Wolfe MM. Transcriptional regulation of the gastric inhibitory (GIP) gene. *Gastroenterology*. 1994;106:A802.
63. Wolfe MM, Tseng C-C, Gelrud D, Jarboe LA. Enhanced trophic properties of endogenous gastrin in aged rats. *Gastroenterology*. 1995;108:A764.
64. Tseng C-C, Wolfe MM. Distinct intracellular signalling pathways of GIP(1-42) and GIP(1-30)-NH₂. *Gastroenterology*. 1995;108:A1012.
65. Tseng C-C, Boylan MO, Jarboe LA, Usdin TB, Wolfe MM. Expression of the glucose-dependent insulintropic peptide (GIP) gene and chronic homologous desensitization of its receptor in diabetic rats. *Gastroenterology*. 1995;108:A1013.
66. Soybel DI, Jarboe LA, Wolfe MM, Delpire E. Omeprazole modulates expression of mRNAs encoding apical H/K ATPase and basolateral Na-K-Cl cotransport in rat gastric mucosa. *Gastroenterology*. 1996;110:A267.
67. Syngal S, Rose SL, Johnson CS, Jarboe LA, Pronovost AD, Wolfe MM. Clinical performance of a rapid immunoassay for occult blood. *Gastroenterology*. 1996;110:A599.
68. Syngal S, Bynum TE, Folkman J, Wolfe MM. Randomized, double-blind, placebo-controlled trial of basic fibroblast growth factor (bFGF) in the healing of gastroduodenal ulcers. *Gastroenterology*. 1996;110:A267.
69. Boylan MO, Wolfe MM. Characterization of chimeric gastric inhibitory polypeptide (GIP) and glucagonlike peptide-1 (GLP-1) receptor proteins. *Gastroenterology*. 1996;110:A1060.
70. Jepeal LI, Boylan MO, Wolfe MM. Functional analysis and tissue-specific expression of the gastric inhibitory polypeptide (GIP) gene promoter. *Gastroenterology*. 1997;112:A1158.
71. Wolfe MM, Jarboe LA. Effects of nutrient protein on gastric inhibitory polypeptide (GIP) gene expression in the rat. *Gastroenterology*. 1997;112:A915.
72. Jepeal LI, Boylan MO, Wolfe MM. Cell-specific expression of gastric inhibitory polypeptide gene (GIP) functions through a GATA motif in a mouse neuroendocrine tumor cell line. *Gastroenterology* 1998;114:A1152.

73. Boylan MO, Jepeal LI, Wolfe MM. Structure of the gene encoding the receptor for rat gastric inhibitory polypeptide (GIP). *Gastroenterology* 1998;114:A1130-1.
74. Yip RGC, Wolfe MM. Gastric inhibitory polypeptide (GIP) receptors are present and functional in rat fat cells. *Gastroenterology* 1998;114:A1192.
75. Glazier KD, Zhao K-B, Jarboe LA, Wolfe MM. Effects of protein on gastric inhibitory polypeptide (GIP) expression in the rat. *Gastroenterology* 1998;114:A1145.
76. Zhao K-B, Jarboe LA, Tseng C-C, Wolfe MM. Effects of glucose-dependent insulinotropic polypeptide (GIP) on acid secretion in the rat. *Gastroenterology* 1999;116:A356.
77. Boylan MO, Jepeal LI, Wolfe MM. Functional analysis of the 5'-flanking region of the rat glucose-dependent insulinotropic polypeptide receptor gene. *Gastroenterology* 1999;116:A593.
78. Yip RGC, Bremer A, Boyd ND, Wolfe MM. Photoaffinity labelling of the GIP receptor with a truncated GIP containing p-benzoylphenylalanine. *Gastroenterology* 1999;116:A656-657.
79. Yip RGC, Choi CJ, Choi M, Wolfe MM. Bioassay for gastric inhibitory polypeptide (GIP) using a recombinant receptor and cAMP-responsive reporter system. *Gastroenterology* 2000;118:A1112.
80. Rana B, Wolfe JR, Crimmins G, Sinclair NF, Choi C, Wolfe MM. Gastrin-induced gastrointestinal tumor growth is mediated through β -catenin and cyclin D1. *Gastroenterology* 2000;118:A561.
81. Wolfe MM, Jarboe LA, Nimmagadda K, Barrison AF. Use and misuse of proton pump inhibitors in clinical practice. *Gastroenterology* 2000;118:A466.
82. Jepeal Li, Boylan MO, Wolfe MM. Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene through a PDX-1 motif in a mouse neuroendocrine tumor cell line. *Gastroenterology* 2001;120:A-124.
83. Rana B, Choi C, Crimmins GM, Wang TC, Pestell RG, Albanese C, Wolfe MM. Cyclin D1 mediates the trophic properties of gastrin in gastric adenocarcinoma. *Gastroenterology* 2001;120:A-662.
84. Yao M, Rana B, Wolfe MM. COX-2 selective inhibition reverses the trophic properties of gastrin. *Gastroenterology* 2001;120:A-39.
85. Saha JK, Wang T, Richardson S, Trocha M, Shumway M, Garvey D, Letts LG, Wolfe MM, Tam SW. Gastroprotective and enhanced anti-ulcerogenic activities in rats of a new class of proton pump inhibitor containing nitric oxide donor moiety nitrosothiol. *Gastroenterology* 2001;120:A-144-5.

86. Triafilopoulos G, DiBaise JK, Nostrant TT, Stollman NH, Anderson PK, Wolfe MM, *et al.* Long-term experience with the Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. *Gastrointest Endosc* 2001;53:.
87. Yao M, Lam EC, Kelly CR, Luk P, Kwong EC, Kargman S, Evans J, Wolfe MM. Cyclooxygenase-2 (COX-2) inhibition attenuates the growth and metastatic potential of colorectal carcinoma (CRC) in mice. *Gastroenterology* 2002;122:A-4.
88. Yao M, Lam EC, Kelly CR, Wolfe MM. Cyclooxygenase-2 inhibition reduces the proliferative and invasive properties of colorectal adenocarcinoma cells. *Gastroenterology* 2002;122:A-240.
89. Song DH, Wolfe MM. The Effects of gastrin in the wnt signaling pathway in colorectal adenocarcinoma. *Gastroenterology* 2002; 2002;122:A-5.
90. Moore TC, Jepeal JI, Boylan MO, Boyd N, Beer DG, Wolfe MM. Functional gastrin receptors are present on adenocarcinoma cells of esophageal origin. *Gastroenterology* 2002; 2002;122:A-63.
91. Corley DA, Katz P, Wo J, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe MM. Radiofrequency energy to the gastroesophageal junction for treatment of GERD (the Stretta procedure): a randomized, sham-controlled, multi-center clinical trial. *Gastrointest Endosc* 2002;55:AB100.
92. Chang A, Song DH, Wolfe MM. Gastrin stimulation of colorectal cell proliferation is associated with decreased PPAR γ activity and protein levels. *Gastroenterology* 2003; 124:A-304.
93. Song DH, Kaufman J, Wolfe MM. Gastrin stabilizes β -catenin levels in colorectal cancer. *Gastroenterology* 2003; 124:A-281.
94. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM. Cyclooxygenase-2 (COX-2) inhibition retards tumor progression by reducing cell proliferation and invasive potential. *Gastroenterology* 2003; 124:A-134.
95. Wolfe MM, Getty L, Boylan MO, Corkey BE. Glucose-dependent insulinotropic polypeptide (GIP) promotes triglyceride synthesis in adipocytes. *Gastroenterology* 2003; 124:A-30.
96. Singh SK, Krishnan S, Boylan MO, Wolfe MM. Internalization and trafficking of the glucose-dependent insulinotropic polypeptide (GIP) receptor is dependent on intracellular calcium signaling. *Gastroenterology* 2003; 124:A-303-304.
97. Jepeal LI, Fujitani Y, Boylan MO, Wilson CN, Wright CV, Wolfe MM. Cell-specific expression of glucose-dependent insulinotropic polypeptide (GIP) requires the transcription factor PDX-1. *Gastroenterology* 2004; 126:A-556-557.

98. Song DH, Simon J, Getty L, Corkey BE, Wolfe MM. Characterization of glucose-dependent insulinotropic polypeptide (GIP) signaling in adipocytes and pancreatic islet β -cells. *Gastroenterology* 2004; 126:A-9.
99. Yao M, Zhou W, Sangha S, Wolfe MM. Ibuprofen attenuates tumor growth and liver metastasis and enhances efficacy of chemotherapy in colorectal cancer. *Gastroenterology* 2004; 126:A-101.
100. Chang AJ, Song DH, Wolfe MM. Gastrin stimulation of colorectal cancer cell proliferation is mediated in part by activation of ERK1/2 and transactivation of the EGF receptor leading to the proteasomal degradation of PPAR γ . *Gastroenterology* 2005; 128:A-42.
101. Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. The role of glucose-dependent insulinotropic polypeptide (GIP) in adipocyte development and signaling. *Gastroenterology* 2005; 128:A-9.
102. Jepeal LI, Boylan MO, Wolfe MM. Regulation of glucose-dependent insulinotropic polypeptide (GIP) expression in cells of pancreatic and intestinal lineage. *Gastroenterology* 2006; 130:A-55.
103. Chang AJ, Song DH, Wolfe MM. Gastrin-stimulated colorectal cancer proliferation is mediated in part through phosphorylation and subsequent degradation of PPAR γ . *Gastroenterology* 2006; 130:A-131.
104. Yao M, Spina CS, Tangpricha V, Zhou W, Maehr H, Uskokovic M, Adorini L, Holick MF, Wolfe MM. Prevention and treatment of colorectal cancer in mice with vitamin D and its Gemini analogues. *Gastroenterology* 2006; 130:A-180.
105. Krishnan S, Wolfe MM, Schwartz JH, Singh SK. Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport in mouse jejunum in vitro. *Gastroenterology* 2006; 130:A-67.
106. Musson MC, Jepeal JI, Wolfe MM. Evolutionary expression of glucose-dependent insulinotropic polypeptide (GIP). *Gastroenterology* 2007; 132:A585-586.
107. Blanton WP, Prabakaran D, Wang B, Yao M, Wolfe MM. Cyclooxygenase-2 (COX-2) inhibition attenuates the growth of colorectal cancer associated with the use of immunosuppression following transplantation. *Gastroenterology* 2007; 132:A440.
108. Song DH, Kandror V, Wolfe MM. Glucose-dependent insulinotropic polypeptide (GIP) modulates multiple signaling pathways in adipocytes. *Gastroenterology* 2007;132:A-91.
109. Wang B, Prabakaran D, Wolfe MM. Glucose-dependent insulinotropic polypeptide (GIP) stimulates colorectal cancer growth. *Gastroenterology* 2008;134:A27.
110. Musson MC, Jepeal JI, Mabray PD, Zhdanova IV, Wolfe MM. Phylogenetic analysis and examination of evolutionary conservation of GIP expression. *Gastroenterology* 2008;134:A-431.

111. Song DH, Moore T, Wolfe MM. Glucose-dependent insulintropic polypeptide (GIP) enhances adipocyte development and modulates multiple downstream targets of Akt. *Gastroenterology* 2008;134:A-44.
112. Musson MC, Jepeal JI, Mabray PD, Kavanaugh SI, Zhdanova IV, Sower SA, Wolfe MM. Phylogeny of glucose-dependent insulintropic polypeptide (gip) expression: implications for nutrient efficiency and obesity. *Gastroenterology* 2009.
113. Musson MC, Jepeal LI, Sharifnia T, Wolfe MM. Evolutionary conservation of glucose-dependent insulintropic polypeptide (GIP) gene regulation and the enteroinsular axis. *Gastroenterology* 2009.
114. Feuerstein JD, Prabakaran D, Ku J, Bijpuria P, Wolfe MM. Stimulation of pancreatic cancer cell growth by glucose-dependent insulintropic polypeptide (GIP). *Gastroenterology* 2009.
115. Bartoo AC, Schwartz JH, Wolfe MM, Singh SK. Glucose-dependent insulintropic polypeptide (GIP) increases dipeptide transport in mouse small intestine. *Gastroenterology* 2009.
116. Bijpuria P, Feuerstein JD, Prabakaran D, Wolfe MM. Glucose-dependent insulintropic polypeptide (GIP) stimulates colorectal cancer (CRC) cellular proliferation via several intracellular pathways. *Gastroenterology* 2009.
117. Valente E, Goldman JA, Boylan MO, Wolfe MM. Engineering of Murine Embryonic Stem (ES) Cells to Express and Release Human Interferon- α (IFN- α). *Gastroenterology* 2010.